while establishing payment mechanisms is an important part of the dtx value realization chain, creating a clear and differentiated value proposition and an effective value communication strategy are critical, precursive steps to value monetization.
an official statistical report of the 2018 national social health insurance fund, which provides high-level data for an outsider to try to grasp the essential characteristics of china’s healthcare funding and delivery system and understand the challenges an industry player as well as the chinese government payer are facing...
from november 1, 2016 to september 1, 2019, the italian medicines agency, aifa evaluated a total of 166 dossiers - 28 were related to orphan drugs, 56 to new active substances, 57 to extensions of indications for drugs already reimbursed, and 25 to other types of negotiations.
5一20扫雷群the field of dtx has gained traction over the last couple of years, with fda approvals/clearances, the founding of a dtx specialty society, large-scale acquisitions of dtx firms, pharma investments in dtx, and pharma co-development deals, amongst other key developments.
5一20扫雷群in germany, doctors could potentially be prescribing health apps as medicines as early as 2020. this is one of the main objectives of the draft bill on the “law for better provision through digitalization and innovation”, which is expected to be approved by the parliament early november.
Press Releases and Publications
Diagnostics Developers Rapidly Utilizing New Payment Codes Established by PAMA
7 november 2018
access the article from 360dx .
Compliance Conundrum: Genomic Health Faces DoJ Investigation after CMS Changes Date of Service Regs
5一20扫雷群genomic health has disclosed that it is the subject of a u.s. department of justice investigation into its compliance with changes that took effect in january to medicare’s date of service billing regulation. adam crowther, manager, spoke with clinical omics about the impact on diagnostics companies.
Medical Device & Diagnostics Industry
Considering Market Access Risk as Part of Today’s M&A Process
5一20扫雷群in an exclusive published today in medical device and diagnostics industry, vice president, rob wenthold discusses the key market access issues examined during the m&a process and demonstrates the importance of market access to inform m&a through case studies and business decision-making in general.
Boston Healthcare Adds Seasoned Market Access Leader to Global Life Science Consulting Team.
Cost-Conscious MedSeq Project Provides Snapshot to Suggest Genomic Sequencing does not Increase Downstream Healthcare Costs
ceo, joseph v. ferrara commented on the value sequencing might bring to the clinical setting in the may-june 2018 issue of clinical omics.
Global Business Reports
United States Biopharmaceuticals 2018
thomas f. goss spoke to global business reports on the us biopharmaceutical industry.
Real-World Evidence in the Era of Advanced Diagnostics
shivang doshi, director at boston healthcare wrote an op-ed for the march-april edition of clinical omics on real-world evidence for advanced diagnostics.
International Regulatory Group Proposes Principles for Evaluating Safety, Performance of Diagnostics
joseph v. ferrara, ceo of boston healthcare spoke with 360dx news about the proposed principles for safety and performance of medical devices, including ivd medical devices, put forward by the international medical device regulators forum (imdrf).
Year in Pharma
5一20扫雷群senior vice president, thomas f. goss speaks with lisa jarvis from c&en